Corrigendum/Revised intimation regarding Re-appointment of Managing Director & Chief Executive Officer of the Company- Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) ....

21 August 2026 BSE Limited (Security Code: 524314) Phiroze Jeejeeboy Towers, Dalal Street, Fort, Mumbai- 400 001. Dear Sirs, Sub: Corrigendum / Revised Intimation regarding Re-appointment of Managing Director & Chief Executive Officer of the Company – Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Ref: Earlier intimation dated 29 May 2026 Pursuant to Regulation 30(6) read with Schedule III and other applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”), we refer to our earlier intimation dated 29 May 2026 submitted to the Stock Exchange regarding the re-appointment of Mr. Aalap Prajapati (DIN: 08088327) as the Managing Director & Chief Executive Officer (“CEO”) of the Company. We wish to inform you that, subsequent to the filing of the aforesaid intimation, the Company noticed an inadvertent error in the tenure and corresponding end date of the re-appointment mentioned therein. In the aforesaid intimation dated 29 May 2026, the tenure of re-appointment was inadvertently mentioned as five (5) years commencing from 28 October 2026 to 27 October 2031 (both days inclusive). The Company hereby clarifies that the correct tenure of re-appointment is for a period of three (3) years commencing from 28 October 2026 to 27 October 2029 (both days inclusive). We further clarify that the aforesaid correct tenure and dates were duly stated in the Notice convening the 41st Annual General Meeting of the Company circulated to the shareholders of the Company and placed before them for their approval. The shareholders of the Company, at the 41st Annual General Meeting held on 21 August 2026, have approved the re-appointment of Mr. Aalap Prajapati (DIN: 08088327) as the Managing Director & Chief Executive Officer of the Company for a period of three (3) years commencing from 28 October 2026 to 27 October 2029 (both days inclusive). Except for the aforesaid correction, all other particulars and disclosures contained in the earlier intimation dated 29 May 2026 remain unchanged. We request BSE Limited to kindly take the above correction on record and update/rectify the relevant records accordingly. The revised disclosure containing the corrected details is enclosed herewith as Annexure I. This intimation is also being uploaded on the website of the Company at https://www.gujaratterce.in/announcements/. Thanking you For Gujarat Terce Laboratories Limited Ashka Solanki Company Secretary ANNEXURE I Details with respect to re-appointment of Mr. Aalap Prajapati as the Managing Director & CEO of the Company under Regulation 30(6) read with Para A(7) of Part A of Schedule III of the Listing Regulations and SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13 July 2023 Sr.No. Details of events that needs to be provided Information of such event(s) 1. Reason for change viz. appointment, re- The Board of Directors have at their meeting held today viz. appointment, resignation, removal, death or Friday, 29 May 2026, basis recommendation of the otherwise Nomination and Remuneration Committee, approved the re- appointment of Mr. Aalap Prajapati (DIN: 08088327), as the Managing Director & CEO of the Company, liable to retire by rotation, for a period of 3 (three) years with effect from 28 October 2026 to 27 October 2029 (both days inclusive), subject to approval of the shareholders of the Company at the ensuing 41st Annual General Meeting of the Company 2. Date of appointment/re-appointment/ Date of Re-appointment- 28 October 2026 cessation (as applicable) and term of appointment/re-appointment Term- 3 years commencing from 28 October 2026 to 27 October 2029 (both days inclusive) 3. Brief Profile (in case of appointment) Mr. Aalap Prajapati has over 15 years of experience in the pharmaceutical sector. He possesses experience in the pharmaceutical and healthcare industry with expertise in business strategy, operations management, marketing and business development. He has been actively associated with the Company’s leadership and growth initiatives and plays a key role in driving operational efficiency and long-term business development of the Company. He holds a management qualification from B.K. School of Business Management with specialization in Marketing and Operations. 4. Disclosure of relationships between He is the Son of Mr. Natwarbhai Prajapati who is the Whole- directors (in case of appointment of a Time Director of the Company. director) 5. Information as required pursuant to BSE Mr. Aalap Prajapati is not debarred from holding the office of Circular with ref. no. LIST/COMP/14/201819 director by virtue of any SEBI order or any other such authority and the National Stock Exchange of India Limited Circular with ref. no. NSE/CML/2018/ 24, both dated 20 June 2018 ************************